MedTrace Logo

A Study of RAY1225 in Participants With Type 2 Diabetes

NCT06254274 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 210

Last updated 2025-08-05

No results posted yet for this study

Summary

The main purpose of this study is to learn more about the Tolerability of RAY1225 in participants with type 2 diabetes mellitus. The study will also explore the efficacy of RAY1225. The study will last about six months for each participant.

Conditions

  • T2DM (Type 2 Diabetes Mellitus)

Interventions

DRUG

RAY1225

Administered SC

DRUG

Placebo

Administered SC

Sponsors & Collaborators

  • Guangdong Raynovent Biotech Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-26
Primary Completion
2025-12-20
Completion
2025-12-20

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06254274 on ClinicalTrials.gov